ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)
Dynamics of C-peptide in patients with type 1 diabetes mellitus on the administration of Tolerogenic Dendritic Cells
Tatsiana Mokhort 1 , Alena Mokhort 1 , Volha Shyshko 2 , Yana Minich 3 , Elena Shishko 1 , Natalia Antonevich 3 , Andrei Hancharou 3 & Volha Lazovtseva 2
1Belarusian State Medical University, Endocrinology, Minsk, Belarus; 2Minsk City Clinical Endocrinological Center, Minsk, Belarus; 3The Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus
Introduction: Preserving of C-peptide secretion in type 1 diabetes mellitus (DM1) is an important goal in treatment, as it provides the possibility of optimal compensation. Various approaches are used to achieve this goal. We initiated a study to assess the potential effect of the cell therapy based on autologous Tolerogenic Dendritic Cells on the newly diagnosed DM1 (NCT05207995, ClinicalTrials.gov).
Methods: 4 patients who were injected with Tolerogenic Dendritic Cells were given standard breakfast (carbohydrate content of 50 g). Fasting glycemia was determined in patients, the test was performed with fasting glycemia in the range of 3.8–9.0 mmol/l, short-acting insulin was not administered before breakfast. The test was carried out for 2 hours with the determination of the level of C-peptide at 0, 30, 60, 90 and 120 minutes. The levels of C-peptide after food stimulation were studied with the calculation of AUC (area under curve). Determination of the level of C-peptide is carried out by the method of chemiluminescent enzyme immunoassay on the analyzer Cobas E411 by Roche Diagnostics (Germany).
Results: There were no changes in insulin requirements (0.56±0.16 U/kg vs 0.52±0.18 U/kg during therapy), and basal levels of C-peptide (1.05±0.55 ng/ml vs 1.36±0.47 ng/ml during therapy) after the administration of Tolerogenic Dendritic Cells. When assessing stimulated levels of C-peptide, we detected an increase in AUC from 220.7±111.9 ng/ml×h. up to 317.6±103.2 ng/ml×h. Also, during continuous monitoring of glycemia, the time in the target range (TIR) reached the recommended value (more than 70%) and only in one patient the target level was not reached (TIR was 51%).
Conclusion: Short-term use of Tolerogenic Dendritic Cells is accompanied by an increase in the secretion of C-peptide in the process of food intake.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more